Severe acquired haemophilia A treated with recombinant factor VIIa
نویسندگان
چکیده
منابع مشابه
Recombinant factor VIIa in severe trauma: further study needed
Results Among 301 patients randomized, 143 blunt trauma patients and 134 penetrating trauma patients were eligible for analysis. In blunt trauma, RBC transfusion was significantly reduced with rFVIIa relative to placebo (estimated reduction of 2.6 RBC units, p = 0.02), and the need for massive transfusion (>20 units of RBCs) was reduced (14% vs. 33% of patients; p = 0.03). In penetrating trauma...
متن کاملRecombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
BACKGROUND Recombinant factor VIIa (rFVIIa) is licensed for use in patients with haemophilia and inhibitory allo-antibodies. It is also increasingly being used for off-license indications to prevent bleeding in operations where blood loss is likely to be high, and/or to stop bleeding that is proving difficult to control by other means. OBJECTIVES To assess the effectiveness of rFVIIa when use...
متن کاملInhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
Recombinant factor VIIa (rFVIIa) is a novel prohemostatic drug for patients with hemophilia who have developed inhibitory antibodies. The postulation has been made that hemophilia is not only a disorder of coagulation, but that hyperfibrinolysis due to a defective activation of thrombin activatable fibrinolysis inhibitor (TAFI) might also play a role. In this in vitro study, the potential of rF...
متن کاملCase report on recombinant coagulation factor VIIa in the treatment of three haemophilia A patients with inhibitors in Singapore.
INTRODUCTION We report the first experiences with use of recombinant coagulation Factor VIIa (rFVIIa) in the treatment of haemophilia A patients with inhibitors in Singapore and discuss observations in 3 patients. CLINICAL PICTURE Case 1 bled on two separate occasions into his neck muscles and vocal cord. Case 2 had gross haematuria from bleeding in the renal calyxes. Case 3 bled into the par...
متن کاملGenetic background and inhibitors in previously untreated or minimally treated young patients with severe haemophilia A treated with sucrose-formulated recombinant factor VIII.
Thromb Haemost 2006; 95: 903–5 Dear Sir, The conventional treatment of haemophilia A is the replacement of human factor VIII (FVIII) derived from plasma or recombinant sources. A major complication of therapy is the development of inhibitory antibodies against substituted factor VIII, affecting 20–30% of severely affected haemophilia A patients. Typically, these antibodies develop at therapy on...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Haematology
سال: 1997
ISSN: 0007-1048,1365-2141
DOI: 10.1046/j.1365-2141.1997.3033120.x